8-K: Dermata Therapeutics Announces Corporate Update and Full Year 2024 Financial Results

Dermata Therapeutics reports full year 2024 financial results and provides a corporate update, highlighting progress on clinical trials and collaborations.

Summary

• Dermata Therapeutics announced its full year 2024 financial results and provided a corporate update on March 17, 2025.
• The company expects to announce topline results from its XYNGARI Phase 3 STAR-1 clinical trial by the end of March 2025.
• Dermata entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 for the treatment of axillary hyperhidrosis.
• The company raised $2.55 million in gross proceeds from a private placement financing in January 2025.
• Enrollment in the XYNGARI Phase 3 STAR-1 clinical trial in moderate-to-severe acne was completed in November 2024, with the last patient visit completed in March 2025.
• The company plans to initiate the second XYNGARI Phase 3 STAR-2 clinical trial in moderate-to-severe acne, assuming positive results from the STAR-1 trial.
• As of December 31, 2024, Dermata had $3.2 million in cash and cash equivalents, compared to $7.4 million as of December 31, 2023.
• The company expects its current cash resources to be sufficient to fund operations into the third quarter of 2025.
• Research and development expenses were $8.2 million for the year ended December 31, 2024, compared to $4.1 million for the year ended December 31, 2023.
• General and administrative expenses were $4.3 million for the year ended December 31, 2024, compared to $4.0 million for the year ended December 31, 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is making progress on its clinical trials and collaborations, but it is also experiencing financial challenges, such as a decrease in cash and an increase in net loss.

Positives

• Dermata completed enrollment in its XYNGARI Phase 3 STAR-1 clinical trial.
• The company signed a Clinical Trial Collaboration Agreement with Revance Therapeutics.
• Dermata raised $7.8 million in gross proceeds during 2024 and an additional $2.55 million in January 2025.
• The company expects to announce topline results from the STAR-1 trial by the end of March 2025.

Negatives

• Dermata's cash and cash equivalents decreased from $7.4 million as of December 31, 2023, to $3.2 million as of December 31, 2024.
• The company's net loss increased from $(7.795) million in 2023 to $(12.287) million in 2024.
• The company's current cash resources are expected to fund operations only into the third quarter of 2025.

Risks

• The success of the XYNGARI and DMT410 product candidates is subject to the uncertainties inherent in clinical trials.
• The company's ability to fund operations is dependent on its ability to raise additional capital.
• The company's future results are subject to known and unknown risks, uncertainties, assumptions, and other factors.

Future Outlook

Dermata expects to announce topline results from its XYNGARI Phase 3 STAR-1 clinical trial by the end of March 2025 and plans to initiate the second XYNGARI Phase 3 STAR-2 clinical trial, assuming positive results from STAR-1. The company expects its current cash resources to be sufficient to fund operations into the third quarter of 2025.

Management Comments

• 'I am very proud of what our team has accomplished this year, and we are excited to unblind the topline data from our XYNGARI Phase 3 STAR-1 trial in the coming weeks,' commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer.
• Mr. Proehl also stated that the company expects to deliver on its promise of a planned announcement of topline data in the first quarter of 2025.
• Mr. Proehl believes that Revance sees the potential of the topical botulinum toxin program and will be a great partner to study DMT410 in multiple indications such as hyperhidrosis, acne, and rosacea.

Industry Context

Dermata's collaboration with Revance, a company recently merged with Crown Laboratories, highlights the increasing interest in combining topical treatments with botulinum toxin products for various dermatological conditions. This approach aligns with the industry trend of exploring novel drug delivery methods and combination therapies to improve treatment efficacy and patient outcomes.

Comparison to Industry Standards

• Dermata's focus on medical skin diseases and aesthetic applications aligns with companies like Galderma, Allergan, and Cutera, which also develop and market products in these areas.
• The development of XYNGARI, a topical product candidate derived from a naturally sourced freshwater sponge, represents a unique approach compared to traditional acne treatments like benzoyl peroxide or retinoids.
• The collaboration with Revance to study DMT410 for hyperhidrosis is similar to Allergan's Botox treatment for the same condition, but with a needle-free intradermal delivery method.

Stakeholder Impact

• Shareholders: The announcement of financial results and clinical trial progress may impact the company's stock price.
• Employees: The company's ability to fund operations into the third quarter of 2025 may impact job security.
• Customers: The potential approval of XYNGARI and DMT410 could provide new treatment options for medical skin diseases and aesthetic applications.

Next Steps

• Announce topline results from the XYNGARI Phase 3 STAR-1 clinical trial by the end of March 2025.
• Initiate the second XYNGARI Phase 3 STAR-2 clinical trial in moderate-to-severe acne, assuming positive results from the STAR-1 trial.
• Continue preparation of DMT410 Phase 2a clinical study with Revance.

Key Dates